RxDoctor Payments DataLook up a doctor →

Tareck Kadrie, MD

Neurology · Chattanooga, TNNPI 1700814191

Payments from drug & device makers

$150,436in general payments, 2019–2025

Across 1,595 payments — averaging $94.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$37K
  • Amgen$35K
  • Lilly USA, LLC$26K
  • AbbVie$17K
  • Biohaven Pharmaceuticals, Inc.$15K
  • Biohaven Pharmaceutical Holding Company Ltd.$5K
  • plus $15K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Teva Pharmaceuticals USA, Inc.287$37,122
Amgen61$35,334
Lilly USA, LLC66$25,538
AbbVie(2 entities)300$16,822
Biohaven Pharmaceuticals, Inc.72$15,229
Biohaven Pharmaceutical Holding Company Ltd.21$4,797
Jazz Pharmaceuticals Inc.50$1,391
UCB, Inc.62$1,370
AstraZeneca(2 entities)42$982
Pfizer58$888
EMD Serono, Inc.46$821
Novartis39$762
Biogen42$734
Inspire Medical Systems, Inc.11$634
Axsome Therapeutics, Inc.30$574
Bristol Myers Squibb44$565
CSL Behring24$546
Argenx US, Inc.18$414
Harmony Biosciences LLC33$411
Avadel CNS Pharmaceuticals, LLC18$374
Neurocrine Biosciences, Inc.21$354
Acadia Pharmaceuticals Inc21$354
Lundbeck LLC15$320
Sanofi13$299
Supernus Pharmaceuticals, Inc.20$244
Arbor Pharmaceuticals, Inc.15$240
TG Therapeutics, Inc.7$237
Genentech USA, Inc.13$234
Idorsia Pharmaceuticals US Inc12$210
Neurelis, Inc.7$181
Johnson & Johnson11$160
SK Life Science, Inc.6$152
Alnylam Pharmaceuticals Inc.5$151
Banner Life Sciences, LLC7$142
Avanir Pharmaceuticals, Inc.9$141
Acorda Therapeutics, Inc7$128
Eisai Inc.7$124
Kyowa Kirin, Inc.6$122
Scilex Pharmaceuticals Inc.7$115
Philips North America LLC6$112
Takeda Pharmaceuticals U.S.A., Inc.4$108
Adamas Pharmaceuticals, Inc.4$90
Octapharma USA, Inc.4$85
Resmed Corp4$75
Merz Pharmaceuticals, LLC3$66
Catalyst Pharmaceuticals, Inc.2$49
Currax Pharmaceuticals LLC3$46
Amneal Pharmaceuticals LLC3$46
Ipsen Biopharmaceuticals, Inc2$41
Merck2$40
ZOLL Respicardia, Inc.1$34
Mylan Specialty L.p.2$34
Boston Scientific2$33
Mallinckrodt Enterprises LLC2$31
E.r. Squibb & Sons, L.L.C.2$30
Avion Pharmaceuticals2$29
GE HealthCare1$29
Vanda Pharmaceuticals Inc.1$28
Mallinckrodt Hospital Products Inc.1$27
Tanabe Pharma America, Inc.2$25

How this compares

$150,436 in reported general payments places this provider in the 85th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee →

Medicare billing

Part B allowed, 2024
$1,455,066
Medicare patients
1,037
Services billed
58,589

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Chattanooga

See the full list for Tennessee →

Where these figures come from

Is this you, or does something look wrong? →